Health Care [ 6/12 ] | Biotechnology [ 45/74 ]
NASDAQ | Common Stock
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders.
The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD.
It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; VK2735, a novel dual agonist of the glucagon-like peptide, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy.
The company was incorporated in 2012 and is headquartered in San Diego, California.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Jul 24, 24 | -0.20 Decreased by -5.26% | -0.27 Increased by +25.93% |
| Apr 24, 24 | -0.26 Decreased by -4.00% | -0.28 Increased by +7.14% |
| Feb 7, 24 | -0.25 Increased by +3.85% | -0.25 |
| Oct 25, 23 | -0.23 Decreased by -9.52% | -0.22 Decreased by -4.55% |
| Jul 26, 23 | -0.19 Increased by +17.39% | -0.19 |
| Apr 26, 23 | -0.25 Decreased by -19.05% | -0.24 Decreased by -4.17% |
| Feb 8, 23 | -0.26 Decreased by -62.50% | -0.23 Decreased by -13.04% |
| Oct 26, 22 | -0.21 Decreased by -23.53% | -0.23 Increased by +8.70% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Mar 31, 24 | 0.00 Decreased by N/A% | -27.36 M Decreased by -47.67% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 23 | 436.00 K Increased by +N/A% | -24.61 M Decreased by -30.63% | Decreased by -5.64 K% Decreased by N/A% |
| Sep 30, 23 | 0.00 Decreased by N/A% | -22.53 M Decreased by -46.80% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 23 | 0.00 Decreased by N/A% | -19.23 M Decreased by -19.28% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 23 | 0.00 Decreased by N/A% | -18.52 M Decreased by -16.06% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 22 | 0.00 Decreased by -100.00% | -18.84 M Decreased by -52.44% | Decreased by N/A% Decreased by N/A% |
| Sep 30, 22 | 0.00 Decreased by -100.00% | -15.35 M Decreased by -15.91% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 22 | 0.00 Decreased by -100.00% | -16.12 M Decreased by -4.79% | Decreased by N/A% Decreased by N/A% |